6533b854fe1ef96bd12af487

RESEARCH PRODUCT

Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.

Marcus SchmidtBahriye AktasAndreas SchneeweissPeter KlareAndreas KutscheidtUlrike SoelingMatthias GeberthHans TeschClaudia SchumacherSherko KümmelWiebke HollburgFrank Gerhard Foerster

subject

Response rate (survey)OncologyCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industryFirst linemedicine.medical_treatmentMedizinmedicine.diseaseMetastatic breast cancerSurgerychemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineLong term outcomesCytotoxic T cellskin and connective tissue diseasesbusinessneoplasmsmedicine.drug

description

e12007 Background: B combined with chemotherapy (CT) significantly improves progression-free survival (PFS) and response rate (RR) vs CT alone in the first-line treatment of HER2-negative MBC. In a...

https://doi.org/10.1200/jco.2014.32.15_suppl.e12007